From the Podium to Practice: Managing Advanced CSCC in 2024

Emily S. Ruiz, MD, MPH, Academic Director of Mohs and Dermatologic Surgery Center and the Director of the High-Risk Skin Cancer Clinic at the Dana-Farber Brigham Cancer Center in Boston, discusses key prognostic factors and new treatment options for cutaneous squamous cell carcinoma.

All Clear: Integrating New Psoriasis Topicals Into Practice

New non-steroidal topical psoriasis therapies are changing the way dermatologists treat psoriasis. Linda F. Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Hospital in Detroit, explains how, when, and why she uses these new options.

New Drugs in Dermatology: A Review​

Derm Digest medical editor Ted Rosen, MD, a Professor of Dermatology at Baylor College of Medicine in Houston, discusses the spate of recent U.S. Food and Drug Administration approvals in dermatology from Cabtreo for acne and two new therapies for molluscum contagiosum to secukinumab (Cosentyx, Novartis) for hidradenitis suppurativa, and a new device to aid […]

Study: Melanoma Overdiagnosis Is on the Rise in White People

More than half of all melanoma diagnoses among white Americans may be overdiagnoses, according to a new study in BMJ Evidence-Based Medicine. For the study, researchers collected incidence and mortality data from the Surveillance, Epidemiology and End Results 9 registries database. They also used DevCan software to calculate the cumulative lifetime risk of being diagnosed with melanoma between […]

Arcutis’ Zoryve Foam Is Now Available for Seb Derm Treatment in the U.S.

Arcutis Biotherapeutics, Inc.’s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. The U.S. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. Roflumilast foam (Zoryve, Arcutis) will be available via wholesaler and pharmacy […]

Health Canada Approves Galderma’s Restylane SHAYPE for Chin Augmentation

Health Canada has given its nod to Restylane SHAYPE, a hyaluronic acid (HA) injectable designed for temporary augmentation of the chin region. Galderma Restylane SHAYPE will be available in Canada as of February 2024. Other regulatory reviews around the world are ongoing, the Company reports. Powered by new NASHA HD technology from Galderma, Restylane SHAYPE has the highest G’ (“G […]

Caught Red-Handed: Exposing the Secret Life of CD4+ T Cells as Melanoma Warriors

In addition to their role in activating other immune cells, CD4+ T cells may help control melanoma, according to new research in Science Immunology. Researchers used microscopic live imaging to visualize the activities and interactions of CD4+ T cells with other cell types in the tumor microenvironment.  “Our in-depth study, using animal models, unraveled the complex biology of CD4+ […]